Aequus and CDRD to jointly improve cannabinoid-based therapeutics


Canadian specialist pharmaceutical company Aequus Pharmaceuticals has entered a broad research collaboration with the Centre for Drug Research and Development (CDRD).

The research collaboration will help establish pre-clinical safety and efficacy of select cannabinoid-based therapeutics that target neurological movement disorders, such as epilepsy, multiple sclerosis, Parkinson’s disease and Huntington’s disease.

CDRD president and chief executive officer Gordon McCauley said: “Our partnership with Aequus is a great example of the work we do with biotech across the country.

“There is a clear unmet medical need in the area of medical cannabinoid research and development where CDRD and Aequus can collaborate and share their respective expertise that could lead to new cannabinoid therapeutics and a pathway to clinical trials, particularly in neurological movement disorders.”

Headquartered in Vancouver, British Columbia, Canada, CDRD is the national drug development and commercialisation centre in the country.

There is currently no sufficient data available to ensure proper therapeutic treatment protocols regarding the proper dosage and frequency for patients with a wide range of symptoms and disease areas.

"Our partnership with Aequus is a great example of the work we do with biotech across the country."

The collaboration will support preclinical studies, including in vitro and in vivo toxicology, pharmacology, and formulation optimisation in relevant disease models.

Following approvals from Health Canada, these preclinical studies will be conducted at CDRD’s facilities in Vancouver, British Columbia.

Products advanced through the new partnership will be commercialised by Aequus Pharmaceuticals.

The company aims to develop pharmaceutical grade products for patients seeking the use of optimised delivery versions of clinically validated formulations of medical cannabis.


Image: CDRD and Aequus collaborate and share their respective expertise to develop new cannabinoid-based therapeutics. Photo: courtesy of Business Wire.